35666-81-0

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)benzenamine is used as a building block for the synthesis of various biologically active compounds. Its unique structure and potential medicinal properties make it a valuable component in the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical industry, 4-(4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)benzenamine serves as a key intermediate in the synthesis of agrochemicals. Its incorporation into these products can contribute to the development of effective and targeted pest control solutions.
Used in Drug Discovery and Development:
4-(4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)benzenamine is also utilized as a potential target for drug discovery and development. Its unique molecular structure positions it as a promising candidate for the creation of novel pharmaceuticals with specific therapeutic effects.

InChI:InChI=1/C16H11F3N2S/c17-16(18,19)12-5-1-10(2-6-12)14-9-22-15(21-14)11-3-7-13(20)8-4-11/h1-9H,20H2

Upstream product

• 151-50-8 potassium cyanide 
• 67-64-1 acetone 
• 477531-69-4 di(morpholino)cyanoborane 
• 110-91-8 morpholine 
• 75-86-5 2-hydroxy-2-methylpropanenitrile 
• 19355-69-2 2-amino-2-cyanopropane 
• 7677-24-9 trimethylsilyl cyanide 

Downstream Products

• 100617-69-4 4-(1-methyl-1-phenyl-ethyl)-morpholine 
• 1004-14-4 4-isopropyl-morpholine 
• 94576-68-8 α-Morpholino-p-phenyl-isobutyrophenon 
• 494773-23-8 4-(2-(4-bromophenyl)propan-2-yl)morpholine 
• 173336-43-1 2-methyl-2-morpholinopropan-1-amine 
• 62317-19-5 1-(morpholin-4-yl)cyclopentanecarbonitrile 

Relevant academic research and scientific papers

Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B/JARID1B)

KDM5B (also known as PLU-1 and JARID1B) is 2-oxoglutarate and Fe2+ dependent oxygenase that acts as a histone H3K4 demethylase, which is a key participant in inhibiting the expression of tumor suppressors as a drug target. Here, we present the discovery of pyrazole derivatives compound 5 by structure-based virtual screening and biochemical screening with IC50 of 9.320 μM against KDM5B, and its subsequent optimization to give 1-(4-methoxyphenyl)-N-(2-methyl-2-morpholinopropyl)-3-phenyl-1H-pyrazole-4-carboxamide (27 ab), a potent KDM5B inhibitor with IC50 of 0.0244 μM. In MKN45 cells, compound 27 ab can bind and stabilize KDM5B and induce the accumulation of H3K4me2/3, bona fide substrates of KDM5B, while keep the amount of H3K4me1, H3K9me2/3 and H3K27me2 without change. Further biological study also indicated that compound 27 ab is a potent cellular active KDM5B inhibitor that can inhibit MKN45 cell proliferation, wound healing and migration. In sum, our finding gives a novel structure for the discovery of KDM5B inhibitor and targeting KDM5B may be a new therapeutic strategy for gastric cancer treatment.

Transamination of a-amino nitriles

α-Amino nitriles containing a primary amino group undergo transamination with aliphatic and aromatic amines under mild conditions with high yields. A probable reaction mechanism involving intermediate elimination of cyanide ion has been proposed.

One-stage synthesis of adamantyl-containing α-aminonitriles

Reactions of 2-adamantan-2-one, acetone cyanohydrin, and amine lead to the formation of substituted 2-amino-2-cyanoadamantanes. The reaction is of a general character as has been proved by examples on a series of ketones and amines and it proceeds through

KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

The invention is directed to a compound represented by the following structural formula pharmaceutically acceptable salts thereof: (I). Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

Bis(dialkylamino)cyanoboranes: Highly efficient reagents for the Strecker-type aminative cyanation of aldehydes and ketones

a-Dialkylamino nitriles are formed in excellent yields in the reactions of bis(dialkylamino)cyanoboranes with a wide array of carbonyl compounds.